Skip to main content
logo
Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
23.47
+0.91 (4.03%)
At close: Feb 6, 2026, 4:00 PM EST
23.49
+0.02 (0.09%)
After-hours: Feb 6, 2026, 4:10 PM EST

Apellis Pharmaceuticals Revenue by Segment

Period EndingSep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021
Product
690.21M689.03M696.78M709.95M657.44M580.05M490.56M366.28M
Product Growth
4.99%18.79%42.04%93.83%165.87%249.90%434.47%462.71%
Collaboration License and Other
326.18M65.62M79.06M71.41M57.78M48.74M33.51M30.31M
Collaboration License and Other Growth
464.53%34.64%135.91%135.62%125.73%159.80%137.61%193.41%

Product Revenue by Segment

Period EndingSep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021
Syfovre
599.55M600.59M604.58M611.85M558.35M481.67M394.39M275.28M--------
Syfovre Growth
7.38%24.69%53.30%122.26%------------
Empaveli
90.69M88.47M92.22M98.13M99.13M98.42M96.21M91.04M
Empaveli Growth
-8.52%-10.11%-4.15%7.79%14.81%22.81%30.91%39.72%
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.